New hope for recurrent ovarian cancer: Triple-Drug combo trial launches
NCT ID NCT07489300
First seen Mar 29, 2026 · Last updated May 14, 2026 · Updated 7 times
Summary
This study tests a combination of three drugs (Benmelstobart, Anlotinib, and Cyclophosphamide) in 40 adults with recurrent ovarian, fallopian tube, or primary peritoneal cancer. The goal is to see if this treatment can control the disease and improve survival. Participants must have measurable tumors and be in good enough health to tolerate chemotherapy.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OVARIAN CANCER are added.
By submitting, you agree to our Terms of use
Conditions
Explore the condition pages connected to this study.